Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy
| Autor: | Qiang Wei, Wufeng Cai, Lu Yang, Mengzhu Liu, Xiaonan Zheng, Shi Qiu, Pengyong Xu, Kun Jin, Mingming Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Cancer specific mortality medicine.medical_treatment 030232 urology & nephrology Urology 03 medical and health sciences 0302 clinical medicine Prostate Epidemiology medicine Overall mortality Radiotherapy business.industry Prostatectomy Proportional hazards model Hazard ratio Radical prostatectomy Confidence interval Diseases of the genitourinary system. Urology Radiation therapy medicine.anatomical_structure 030220 oncology & carcinogenesis Propensity score matching Ductal adenocarcinoma of the prostate Original Article RC870-923 business |
| Zdroj: | Asian Journal of Urology, Vol 8, Iss 2, Pp 227-234 (2021) Asian Journal of Urology |
| ISSN: | 2214-3882 |
| Popis: | Objective: To evaluate the oncological outcomes of ductal adenocarcinoma of the prostate (DAC) managed with radical prostatectomy (RP) or radiotherapy (RT) and optimize the proper treatment modality to DAC comprehensively. Methods: The cohorts included a total of 528 patients from the Surveillance, Epidemiology and End Results (SEER) database, 354 receiving RP and 174 receiving RT. Cox proportional hazards regressions were performed to assess cancer specific mortality (CSM) and overall mortality (OM) between treatment groups. A competing risk analysis was further conducted. Subgroup analyses by age and level of prostate-specific antigen (PSA) were performed. Propensity score matching was implemented. Results: Patients managed with RP had lower risks of CSM and OM compared with RT (before matching: Hazard ratio [HR]=0.24, 95% confidence interval [CI] 0.13–0.47 and HR=0.26, 95% CI 0.17–0.40, respectively; after matching: HR=0.18, 95% CI 0.04–0.82 and HR=0.28, 95% CI 0.11–0.70, accordingly). Subgroup analyses demonstrated that patients in the middle tertile of the age or with lower tertile PSA level managed with RP took lower risks of OM significantly (HR=0.18, 95% CI 0.06–0.57, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|